Ontology highlight
ABSTRACT: Background
Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker.Methods
We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET scans were obtained postoperatively for RT planning. We used Cox proportional hazards models with OS and PFS as endpoints, to test the prognostic value of FET PET biological tumor volume (BTV).Results
Median follow-up time was 14 months, and median OS and PFS were 16.5 and 6.5 months, respectively. In the multivariate analysis, increasing BTV (HR = 1.17, P?ConclusionLarge BTV on FET PET is an independent prognostic factor of poor OS and PFS in glioblastoma patients. With the introduction of FET PET, we obtain a prognostic index that can help in glioblastoma treatment planning.
SUBMITTER: Poulsen SH
PROVIDER: S-EPMC5281673 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Poulsen Sidsel Højklint SH Urup Thomas T Grunnet Kirsten K Christensen Ib Jarle IJ Larsen Vibeke Andrée VA Jensen Michael Lundemann ML Af Rosenschöld Per Munck PM Poulsen Hans Skovgaard HS Law Ian I
European journal of nuclear medicine and molecular imaging 20160823 3
<h4>Background</h4>Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-<sup>18</sup>F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker.<h4>Methods</h4>We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET sca ...[more]